Evidence map›Paper›PMID 33807495›Full record

ArticleLife (Basel, Switzerland)2021

A Small Molecule Targeting Human MEK1/2 Enhances ERK and p38 Phosphorylation under Oxidative Stress or with Phenothiazines.

Michał Otręba, Johanna Johansson Sjölander, Morten Grøtli, Per Sunnerhagen

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Targeting CaLife (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Michał OtrębaDepartment of Drug Technology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jednosci 8, 41-200 Sosnowiec, Poland.ORCID 0000-0002-7523-7737
Johanna Johansson SjölanderDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.
Morten GrøtliDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.
Per SunnerhagenDepartment of Chemistry and Molecular Biology, University of Gothenburg, S-405 30 Gothenburg, Sweden.
University of Gothenburg · SEMedical University of Silesia · PL

Funding

Medical University of Silesia PCN-2-034/K/O/FSwedish Cancer Fund 2016-0708Swedish Cancer Fund 2019-0133
6 · The paper itself

Abstract

Small molecules are routinely used to inhibit protein kinases, but modulators capable of enhancing kinase activity are rare. We have previously shown that the small molecule INR119, designed as an inhibitor of MEK1/2, will enhance the activity of its fission yeast homologue, Wis1, under oxidative stress. To investigate the generality of these findings, we now study the effect of INR119 in human cells under similar conditions. Cells of the established breast cancer line MCF-7 were exposed to H

Indexed as

MAP kinase pathwaysphenothiazinesredox signallingsmall molecule kinase modulator

Identifiers

PMID33807495
PMCPMC8066054
OpenAlexW3145417191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.